If you have been reading about DAC and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Updated 2026-07-05. Numbers and descriptions here follow the published literature rather than marketing material.
CJC-1295 is a synthetic peptide belonging to the growth hormone-releasing hormone analog family. It comprises twenty-nine amino acid residues derived from the N-terminal region of natural GHRH. The molecule incorporates several non-natural substitutions that increase resistance to enzymatic degradation. These modifications extend its activity compared with the native hormone fragment. Researchers use it to study pituitary growth hormone secretion in laboratory and clinical settings. This compound is distinct from native GHRH in its stability profile.
Two principal forms appear in the literature and in research supply. One carries a drug affinity complex, a maleimide-based group that forms a covalent bond with circulating albumin. This linkage slows clearance and produces a long-lasting elevation of peptide levels. The other form lacks that group and is often labeled MOD GRF(1-29). It has a much shorter circulation time. Both variants retain the same core receptor-binding sequence. Reported half-lives differ substantially between the two.
At the pituitary, the peptide binds the growth hormone-releasing hormone receptor on somatotroph cells. Receptor activation raises intracellular cyclic AMP and triggers release of stored growth hormone. Somatostatin and other hypothalamic signals modulate this response. Negative feedback from insulin-like growth factor 1 also influences output. The same regulatory architecture operates with the native hormone. Whether the synthetic analog alters feedback dynamics over repeated exposure remains an open question. Most published receptor work uses cell models rather than intact human systems.
Reverse-phase high-performance liquid chromatography is the standard tool for purity assessment. The technique separates the target peptide from truncated or modified byproducts. Mass spectrometry confirms molecular weight and supports sequence verification. Electrospray ionization and matrix-assisted laser desorption are both used. Amino acid analysis provides an independent check on composition. Purity values are commonly reported as area percentage from the chromatogram. Residual trifluoroacetate and water content are also measured in many quality programs.
Batch-to-batch consistency depends on solid-phase peptide synthesis and subsequent purification. Coupling efficiency, resin choice, and cleavage conditions all affect the final profile. Counter-ion content and moisture can shift the apparent mass of a batch. Documentation typically includes a certificate of analysis with chromatograms and spectra. Independent verification by a second laboratory is sometimes requested. Whether a given certificate reflects the actual vial contents depends on chain of custody. Analytical methods themselves carry uncertainty that should be stated alongside results.
Lyophilized material is typically stored at minus twenty degrees Celsius or lower. Keeping the vial dry and protected from light preserves peptide integrity. Repeated freeze-thaw cycles can cause aggregation or loss of activity. Once dissolved, solutions are generally kept at two to eight degrees Celsius. Stability data for reconstituted solutions vary, and long-term behavior is not fully established. Working aliquots reduce the number of times a stock container is opened.
| Property | Value | Notes |
|---|---|---|
| Molecular weight, DAC form | About 3647 Da | Varies with salt form |
| Molecular weight, non-DAC form | About 3358 Da | MOD GRF(1-29) |
| Solubility class | Water soluble | Also dissolves in polar solvents |
| Reported half-life, DAC form | About five to eight days | Values from human studies |
| Common synonyms | CJC-1295; MOD GRF(1-29) | Name depends on variant |
The peptide backbone includes a D-alanine at position two, which resists cleavage by dipeptidyl peptidase IV, and several other substitutions that reduce degradation. Its molecular weight is roughly 3.4 kDa without the linker and about 3.6 kDa with it. The molecule is water soluble and is normally supplied as a lyophilized powder. Precise sequence and mass values depend on which variant is described, so technical documents usually state the exact form being referenced.
CJC-1295 is a synthetic peptide designed as a long-acting analogue of growth hormone-releasing hormone (GHRH). Its structure derives from the first 29 amino acids of native GHRH, a fragment often called GRF(1-29). Four substitutions were introduced to slow enzymatic breakdown and extend activity relative to the natural sequence. The compound was developed by ConjuChem as part of a broader effort to improve the pharmacokinetic profile of peptide hormones. It is studied in laboratory and clinical research settings rather than appearing as a naturally occurring substance.
Two related forms circulate in technical discussion under the same family name. The original version carries a drug affinity complex (DAC) that binds covalently to serum albumin after administration, and this linkage substantially extends circulation time. A second form, frequently written as modified GRF(1-29) or CJC-1295 without DAC, lacks that linker and clears much faster. The naming is a frequent source of confusion because the shorthand CJC-1295 can refer to either form depending on the source. Reports sometimes fail to specify which variant was studied.
Four amino acid substitutions separate the modified backbone from the parent GRF(1-29) sequence. These changes reduce recognition by dipeptidyl peptidase IV and related proteases, extending the interval before degradation. Development work in this area sought longer-acting GHRH analogs for endocrine investigation. Published descriptions treat the substitution set as a defining property of the core sequence, while the albumin-binding linker is described separately as an optional addition to that same backbone.
CJC-1295 is a synthetic peptide analog of growth hormone-releasing hormone, constructed on the 29-amino-acid fragment designated GRF(1-29). The name began as an internal development code during the 1990s and later spread through research supply catalogs and discussion forums. The molecule does not occur in nature; its sequence is engineered rather than isolated from tissue. Two related compounds are sold under this single label, and they differ by one appended chemical group that strongly influences how long the peptide remains in circulation.
=== Alkenes === Alkenes often produce stronger molecular ion peaks than alkanes due to the lower ionization energy of a pi electron than a σ electron. After the ionization, double bonds can migrate easily, resulting in almost impossible determination of isomers. Allylic cleavage is most significant fragmentation mode due to resonance stabilization.
== Company history == The company traces its roots to William Lines, Inc., which began as a shipping business founded by William Chiongbian on December 13, 1945, in Cebu City. He named one of its first vessels, the MV Victoriano, after his father; the ship made its maiden voyage serving the routes from Cebu to Tagbilaran, Bohol, and Siquijor, then to Plaridel and Ozamiz. The company was later incorporated on May 26, 1949. From the 1970s to the 1990s, the company introduced several flagship vessels, including MV Cebu City (1972), MV Doña Virginia (1980), and MV Sugbu (1989), and grew to become one of the largest shipping companies in the Philippines during that period. In the 1990s, William Lines introduced the Mabuhay Series, comprising the company's largest and most luxurious vessels, designed to compete with rival fleets, including Sulpicio Lines and Aboitiz's SuperFerry ships. The first ship of the series, the Wilines Mabuhay 1, was acquired from Japan and was part of the well-known Sunflower series of vessels. Subsequently, William Lines added more ships to the Mabuhay Series, including Mabuhay 2, 3, 5, and 6. In December 1995, William Lines acquired the assets of Gothong Lines and Aboitiz Shipping Corporation through a ₱5.68 billion share-swap deal, issuing new William Lines shares to the two companies in exchange for their shipping properties. The merger consolidated the operations of the three shipping firms, forming William, Gothong and Aboitiz Inc. (WG&A), which became the largest domestic shipping company in the Philippines.
Semen can be used successfully almost indefinitely after cryopreservation in a sperm bank. The longest reported successful storage is 22 years. It can be used for sperm donation where the recipient wants the treatment in a different time or place or as a means of preserving fertility for men undergoing vasectomy or treatments that may compromise their fertility, such as chemotherapy, radiation therapy or surgery.
Ayahuasca has a number of major contraindications due to its action as a monoamine oxidase inhibitor (MAOI) and the potential for serious drug interactions. These include concomitant use with serotonergic agents like selective serotonin reuptake inhibitors (SSRIs), MDMA, and dextromethorphan (DXM) due to risk of serotonin syndrome, sympathomimetics like amphetamines and cocaine due to risk of hypertensive crisis, and certain other drugs. Little information is available on ayahuasca in people with cardiovascular disease and whether there may be contraindications in this area. In any case, it has been said that cardiovascular problems, as well as endocrine problems, abnormal lipid metabolism, glaucoma, fever, and pregnancy are all contraindications of ayahuasca. Certain psychiatric disorders such as psychosis or bipolar mania or family history of such conditions may also be contraindications of ayahuasca.
Sources: en.wikipedia.org
Consequently, the Royal College of General Practitioners and the Royal College of Physicians ended their corporate partnerships as it would be in breach of their ethical guidance. The Novo UK General Manager, Pinder Sahota, chose to resign as President of the ABPI prior to the suspension. In August 2023, one of the first lawsuits was filed alleging that Novo's Ozempic and Eli Lilly's Mounjaro (tirzepatide) caused severe gastrointestinal side effects, including gastroparesis. The lawsuit was brought on behalf of Jaclyn Bjorklund, a Louisiana woman represented by Morgan & Morgan, who alleged that she suffered persistent vomiting and other serious injuries after using the drugs and that the manufacturers failed to adequately warn patients and physicians about the risks. In September 2023, the law firm Motley Rice filed a lawsuit on behalf of a Pennsylvania woman who had been taking weight-loss drug Wegovy. The lawsuit alleges that the plaintiff experienced severe stomach cramping, vomiting, and nausea requiring hospitalization, and that Novo failed to adequately warn patients about the risk of gastroparesis. In February 2024, the United States Judicial Panel on Multidistrict Litigation ordered that 55 lawsuits pending in federal courts be consolidated into a multidistrict litigation. The majority of the cases were against Novo, but some were brought against Eli Lilly. As of August 2024 there were 235 active Ozempic lawsuits.
== E == efficacy – empirical – encephalitis – end-stage disease – endemic – endogenous – endoscopy – endotoxin – endpoint – enteric – enteritis – entry inhibitors – Env – envelope – enzyme – enzyme-linked immunosorbent assay (ELISA) – eosinophil – eosinophilic folliculitis – epidemic – epidemiological surveillance – epidemiology – epithelium – epitope – Epstein-Barr virus (EBV) – erythema – erythema multiforme – erythrocytes – etiology – exogenous – exotoxin – expanded access – experimental drug – expression system
=== Metals === The biological half-life of caesium in humans is between one and four months. This can be shortened by feeding the person prussian blue. The prussian blue in the digestive system acts as a solid ion exchanger which absorbs the caesium while releasing potassium ions. For some substances, it is important to think of the human or animal body as being made up of several parts, each with its own affinity for the substance, and each part with a different biological half-life (physiologically-based pharmacokinetic modelling). Attempts to remove a substance from the whole organism may have the effect of increasing the burden present in one part of the organism. For instance, if a person who is contaminated with lead is given EDTA in a chelation therapy, then while the rate at which lead is lost from the body will be increased, the lead within the body tends to relocate into the brain where it can do the most harm.
M(CO)n → M(CO)n−1 + CO M(CO)n−1 + L → M(CO)n−1L The dissociation energy is 105 kJ/mol (25 kcal/mol) for nickel tetracarbonyl and 155 kJ/mol (37 kcal/mol) for chromium hexacarbonyl. Substitution in 17-electron complexes, which are rare, proceeds via associative mechanisms with a 19-electron intermediates.
== Applications == To date, PAMPA models have been developed that exhibit a high degree of correlation with permeation across a variety of barriers, including Caco-2 cultures, the gastrointestinal tract, blood–brain barrier and skin. The donor and/or acceptor compartments may contain solubilizing agents, or additives that bind the drugs as they permeate. To improve the in vitro - in vivo correlation and performance of the PAMPA method, the lipid, pH and chemical composition of the system is often designed with biomimetic considerations in mind. Although active transport is not modeled by the artificial PAMPA membrane, up to 95% of known drugs are absorbed by passive transport. Some experts support a lower figure, so the amount is open to some interpretation. Microtiter plates with 96 wells can be used for the assay which increases the speed and lowers the per sample cost.
Sources: en.wikipedia.org
In other places, such as Australia, suvorexant is a prescription-only medicine and is not a controlled drug. Suvorexant is not available in generic formulations. Besides suvorexant, other orexin receptor antagonists like lemborexant and daridorexant have also been introduced.
=== Coup-proofing === In what is referred to as "coup-proofing", regimes create structures that make it hard for any small group to seize power. These coup-proofing strategies may include the strategic placing of family, ethnic, and religious groups in the military; creation of an armed force parallel to the regular military; and development of multiple internal security agencies with overlapping jurisdiction that constantly monitor one another. It may also involve frequent salary hikes and promotions for members of the military, and the deliberate use of diverse bureaucrats. Research shows that some coup-proofing strategies reduce the risk of coups occurring. However, coup-proofing reduces military effectiveness, and limits the rents that an incumbent can extract. One reason why authoritarian governments tend to have incompetent militaries is that authoritarian regimes fear that their military will stage a coup or allow a domestic uprising to proceed uninterrupted – as a consequence, authoritarian rulers have incentives to place incompetent loyalists in key positions in the military. A 2016 study shows that the implementation of succession rules reduce the occurrence of coup attempts. Succession rules are believed to hamper coordination efforts among coup plotters by assuaging elites who have more to gain by patience than by plotting. According to political scientists Curtis Bell and Jonathan Powell, coup attempts in neighbouring countries lead to greater coup-proofing and coup-related repression in a region.
Overall, according to a study in British Columbia, approximately 2.3 children per 100,000 births (1 in 43,000) have some form of glycogen storage disease. In the United States, they are estimated to occur in 1 per 20,000–25,000 births. Dutch incidence rate is estimated to be 1 per 40,000 births. While a Mexican incidence showed 6.78:1000 male newborns. Within the category of muscle glycogenoses (muscle GSDs), McArdle disease (GSD-V) is by far the most commonly diagnosed.
Ellen McLain (born 1952 or 1953) is an American voice actress. She is best known for providing the voice of GLaDOS, the primary antagonist of the Portal video game series, the Combine Overwatch AI in Half-Life 2, and the Administrator, the announcer in Team Fortress 2. Her voice roles also include the Jaeger A.I. in Pacific Rim and The Witch in Left 4 Dead 2.
The number of actions needed to get the drug increases every time, so it becomes harder and harder to get the drug. The highest number of actions that the animal or human is willing to do to get the drug is called the break point. The higher the break point, the more the animal or human wants the drug. In contrast to the classical stimulants such as amphetamine, the effects of modafinil depend on what the animals or humans have to do after getting the drug. If they have to do a performance task, like solving a puzzle or remembering something, modafinil makes them work harder for it than placebo, and the subjects wanted to self-administer modafinil. But if they had to do a relaxation task, like listening to music or watching a video, the subjects did not want to self-administer modafinil. This suggests that modafinil is more rewarding when it helps the animals or humans do something better or faster, especially considering that modafinil is not commonly abused or depended on by people, unlike other stimulants.
Sources: en.wikipedia.org
It is a synthetic peptide modeled on growth hormone-releasing hormone. The molecule is used in research on pituitary growth hormone secretion. It differs from the natural hormone through several stabilizing substitutions.
The DAC form carries a maleimide group that binds albumin and extends circulation time. The non-DAC form lacks this group and clears much faster. Both share the same receptor-binding core.
It targets the growth hormone-releasing hormone receptor on pituitary somatotroph cells. Activation raises cyclic AMP and promotes growth hormone release. Normal feedback pathways remain part of the response.
The powder is normally held at minus twenty degrees Celsius or below. Light and moisture exposure should be minimized. Repeated warming and cooling cycles are avoided.